Fortis Healthcare Ltd. (FORTIS) AI Stock Analysis

• Market Cap: ₹824.98B
• Dividend Yield: 0.09%
• Average Volume (3M): 66.29K
• Price to Earnings (P/E): 94.3
• Beta (1Y): 1.06
• Revenue Growth: 14.04%
• EPS Growth: 32.99%
• Country: IN
• Employees: 12,088
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 3.40
• Shares Outstanding: 754,958,100
• 10 Day Avg. Volume: 118,360
• 30 Day Avg. Volume: 66,292
• PEG Ratio: 2.28
• Price to Book (P/B): 5.83
• Price to Sales (P/S): 6.68
• P/FCF Ratio: 90.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹921.67
• Price Target Upside: -12.52% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 64 Neutral
• Price Target: ₹1,175.00 ▲(11.52% Upside)

Fortis Healthcare Ltd. has a strong financial foundation with consistent revenue growth and improved profitability, which is the most significant factor in its score. However, the technical analysis indicates potential overbought conditions, and the high P/E ratio suggests overvaluation, which tempers the overall score.

Fortis Healthcare Ltd. Business Overview & Revenue Model

Company Description

Fortis Healthcare Ltd. (FORTIS) is a leading integrated healthcare provider in India, offering a wide range of services across various sectors including hospitals, diagnostics, and day care specialty services. The company operates a network of multi-specialty hospitals and is known for its advanced medical technology and high-quality patient care. Fortis aims to deliver comprehensive healthcare solutions through its hospitals, outpatient services, and diagnostic centers, catering to both domestic and international patients.

How the Company Makes Money

Fortis Healthcare generates revenue primarily through its hospital operations, which include inpatient and outpatient services. The company charges patients for medical treatments, surgeries, and diagnostic services. Additionally, it earns revenue from its diagnostic centers by providing laboratory and imaging services. Fortis has also established partnerships with insurance companies to facilitate cashless treatment options for insured patients, which contributes to a steady stream of income. Furthermore, the company may engage in strategic collaborations and alliances with healthcare providers and technology companies to enhance service delivery and expand its market reach, thereby positively impacting its earnings.

Fortis Healthcare Ltd. Financial Statement Overview

Summary

Fortis Healthcare Ltd. demonstrates strong financial performance with consistent revenue growth and improved profitability. The income statement shows robust gross and net profit margins. The balance sheet is stable with a healthy equity ratio, though total debt levels require monitoring. Cash flow is positive with strong cash-generating ability, despite some volatility in capital expenditures.

Income Statement

Fortis Healthcare Ltd. has demonstrated a strong income statement performance with consistent revenue growth, particularly from 2021 to 2025. The gross profit margin has remained robust, averaging above 40% in recent years, indicating effective cost management. Net profit margins have improved significantly, turning from negative to positive, showcasing enhanced profitability. EBIT and EBITDA margins have also seen notable improvements, indicating operational efficiency gains.

Balance Sheet

The company's balance sheet is solid with a healthy equity ratio, reflecting financial stability. The debt-to-equity ratio has been improving, suggesting prudent financial management and reduced leverage risk. Return on equity has increased, highlighting better efficiency in generating profits from shareholders' equity. However, the total debt level remains a consideration, though manageable given the company's growth trajectory.

Cash Flow

Fortis Healthcare Ltd. exhibits a positive cash flow trajectory, with significant growth in free cash flow over the years. The operating cash flow to net income ratio indicates strong cash-generating ability relative to accounting profits. However, fluctuations in capital expenditures and investing cash flows highlight potential volatility in future cash flows. Overall, cash flow management appears effective, supporting the company's expansion and operational needs.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	77.83B	77.86B	68.97B	62.98B	57.18B	40.30B
Gross Profit	30.52B	45.86B	39.73B	23.08B	32.25B	20.72B
EBITDA	14.98B	15.00B	11.87B	10.37B	9.96B	3.47B
Net Income	7.74B	7.74B	5.99B	5.89B	5.55B	-1.10B
Balance Sheet
Total Assets	136.92B	136.92B	132.89B	124.34B	118.85B	111.55B
Cash, Cash Equivalents and Short-Term Investments	5.08B	5.08B	6.00B	3.66B	4.13B	4.16B
Total Debt	24.75B	24.75B	11.55B	9.26B	12.55B	15.31B
Total Liabilities	45.22B	45.22B	47.33B	43.33B	48.76B	44.37B
Stockholders Equity	89.17B	89.17B	76.63B	72.42B	61.78B	61.20B
Cash Flow
Free Cash Flow	0.00	5.77B	1.58B	3.75B	6.50B	2.67B
Operating Cash Flow	0.00	14.24B	11.00B	8.22B	8.65B	4.85B
Investing Cash Flow	0.00	-7.79B	-8.86B	-3.74B	-5.14B	-1.35B
Financing Cash Flow	0.00	-7.14B	-864.58M	-4.71B	-5.17B	-1.43B

Fortis Healthcare Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1053.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FORTIS, the sentiment is Positive. The current price of 1053.6 is above the 20-day moving average (MA) of 1045.05, above the 50-day MA of 986.84, and above the 200-day MA of 774.81, indicating a bullish trend. The MACD of 26.90 indicates Positive momentum. The RSI at 55.65 is Neutral, neither overbought nor oversold. The STOCH value of 12.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:FORTIS.

Fortis Healthcare Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NH	―	₹354.06B	44.87	―	0.26%	12.09%	-2.79%
LALPATHLAB	―	₹263.68B	50.51	―	0.76%	10.57%	34.11%
MANKIND	―	₹1.02T	53.21	―	0.04%	21.66%	-4.92%
FORTIS	―	₹824.98B	94.33	―	0.09%	14.04%	32.99%
APOLLOHOSP	―	₹1.14T	72.27	―	0.24%	14.31%	51.71%
METROPOLIS	―	₹98.98B	64.71	―	―	12.86%	10.42%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Fortis Healthcare Ltd. Corporate Events

Fortis Healthcare Completes Postal Ballot Notice Transmission

Fortis Healthcare Limited announced the publication of newspaper advertisements regarding the completion of electronic transmission of a Postal Ballot Notice to its members. This announcement is part of the company’s compliance with SEBI regulations, ensuring transparency and communication with its stakeholders.

Fortis Healthcare Reports Debt Securities Details

Fortis Healthcare Limited has reported details of its debt securities issued through private placement as per the SEBI Master Circular. The company has listed debt securities with an issuance date of December 19, 2024, and a maturity date of December 19, 2029, with an initial coupon rate of 8.486% per annum. This announcement is part of their compliance with regulatory requirements and reflects the company’s ongoing financial management strategy.

Fortis Healthcare Executes Tripartite Agreement for Greater Noida Facility

Fortis Healthcare Limited announced the execution of a tripartite agreement involving its wholly owned subsidiary, International Hospital Limited (IHL), Uttar Pradesh Industrial Development Authority (UPSIDA), and R.R. Lifesciences Pvt Ltd. This agreement pertains to the sub-leasing of hospital land, building, and equipment in Greater Noida, which is expected to enhance Fortis Healthcare’s operational capabilities and strengthen its market position.

Fortis Healthcare Expands Operations with New Tripartite Agreement

Fortis Healthcare Limited has announced the execution of a tripartite agreement involving the Uttar Pradesh Industrial Development Authority, R.R. Lifesciences Pvt Ltd, and International Hospital Limited, a wholly-owned subsidiary of Fortis. This agreement pertains to the sub-leasing of hospital land, building, and equipment in Greater Noida to International Hospital Limited, which could enhance Fortis’s operational capacity and strengthen its position in the healthcare sector.